Most Popular
Newsletter
CRISPR-Pro Versus ES Cell Targeting：Which is the Optimal Solution?
Mar 19, 2020
With the rapid advancement of biomedical technology in recent years, customized treatment methods such as targeted medicine, immunotherapy, and gene therapy have become the main directions of biomedical innovation - which is intimately related to the development of gene-editing technology. Read More >
Newsletter
BALB/c Strains Now Available for TurboKnockout® Embryonic Stem Cell (ESC) Mediated Services
Mar 18, 2020
Cyagen is proud to announce the availability of BALB/c mouse models for all embryonic stem cell (ESC) based gene targeting services, including our proprietary TurboKnockout® technology. Read More >
Newsletter
Research Trend
White Paper
COVID-19
Researching the New Coronavirus, SARS-CoV-2: Applications for Animal Models
Mar 10, 2020
The novel coronavirus, now officially designated as SARS-CoV-2, was first identified in Wuhan, Hubei Province, China in December of 2019. This virus has led to an outbreak of COVID-19 (Coronavirus Disease in 2019), which is associated with acute respiratory illness and infection, as is common for diseases caused by the coronavirus family. Read More >
Research Trend
Breaking News
White Paper
COVID-19
Coronaviruses and SARS-CoV-2 – Host Receptor-Mediated Infection Mechanisms & Potential Antiviral Treatments
Mar 10, 2020
At the end of 2019, a large-scale illness broke out from Wuhan, Hubei Province - a central province of China. The virus that cased this illness could enter the respiratory tract through droplets - moreover, the increasingly busy traffic conditions and travel around the holiday season made the virus spread extremely rapidly. Read More >
Research Trend
Breaking News
White Paper
COVID-19
Beyond ACE2: Additional Targets of Significance for Coronavirus Research
Mar 10, 2020
At present, the prevention and treatment of coronavirus is the most urgent issue for scientific and medical research. In addition to the ACE2 host receptor target that is being highly focused on, what other targets deserve the attention of current coronavirus researchers? Read More >
Newsletter
Breaking News
Cyagen Knockout Catalog Models Now Available in the US & Europe
Mar 04, 2020
As the leader in custom genetically engineered mouse and rat models, Cyagen has generated thousands of custom knockout (KO), knockin (KI), and transgenic rodent lines for its customer base that covers over 2,000 universities and companies worldwide. This rapid growth has seen the number of publications citing Cyagen in high-impact journals such as Nature, Cell and Science increase to over 3,400 in record time. Read More >
Breaking News
Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
Feb 27, 2020
Cyagen Biosciences Suzhou Inc. closed a 285 million RMB (equivalent to about $41 million USD) Series B financing as of Feb 25. The investments are from funds managed by CMS Capital, GF Qianhe and GF Xinde which are both wholly owned by GF securities, and Guanghua Investment respectively. Read More >
Research Trend
Breaking News
White Paper
COVID-19
White Paper: Infectivity and Immune Mechanisms of Coronaviruses & SARS-CoV-2
Feb 27, 2020
An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan at the end of 2019 - having since brought a huge impact on the lives of people both in China and abroad. Read More >
Newsletter
Research Trend
A Guide to Stem Cell Research: Disease Models and Clinical Applications in 2020
Jan 21, 2020
This guide offers a quick introduction to stem cells, current stem cell research efforts, widely-used stem cell treatments, and clinical trials currently underway in 2020. Read More >
Newsletter
Cyagen’s Discount of the Decade Ends December 31st
Dec 06, 2019
Are you considering custom animal models to accelerate your next research project? Cyagen's Discount of the Decade Event can help you extend your research with big savings for multiple projects - the more animal models you order from any eligible service, the more you save! Read More >